Axon's COVID-19 vaccine shows promise for elderly population

By The Science Advisory Board staff writers

September 10, 2020 -- Clinical-stage biotechnology company Axon Neuroscience has touted results from a preclinical trial for its COVID-19 vaccine candidate.

The ACvac1 vaccine contains key elements of the SARS-CoV-2 spike protein. It is designed to produce an immune response in healthy individuals in order to prevent the novel coronavirus from infecting host cells.

Axon Neuroscience lab technician.
Axon Neuroscience lab technician. Image courtesy of Axon Neuroscience.

In the preclinical trial, mice vaccinated with ACvac1 produced a high titer of serum antibodies against the part of the SARS-CoV-2 spike protein that allows it to infect cells and replicate. The antibodies also effectively neutralized the live novel coronavirus without the mice showing adverse reactions, according to Axon.

The company is now working toward testing the peptide-based vaccine in a clinical trial. The target population is elderly individuals, who often cannot tolerate high vaccine doses due to adverse effects.

The ACvac1 vaccine platform is based on the company's years of research into using immunogenic peptide vaccines for neurodegenerative disorders in patients age 70 or older, Axon noted. The company intends to begin clinical trials as soon as the fourth quarter of 2020.

New technique reins in inflammatory response of adjuvants
Adjuvants are often added to vaccines as a method for promoting an immune response in recipients. But what happens when that immune response goes haywire,...
Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...
Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward...
Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.
Protein engineering creates highly potent experimental SARS-CoV-2 vaccine
A bioengineering technique that utilizes various naturally occurring sequences and de novo design of messenger RNA (mRNA) components was applied to develop...

Copyright © 2020

Cell Bio 2022
December 3-7
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter